London-based Sava Technologies has raised $19 million in Series A funding to propel development of its wearable biosensor, a next-gen continuous glucose monitor (CGM).
Unlike traditional CGMs, Sava’s device uses a proprietary multi-molecule sensor that detects biomarkers beneath the skin in real-time. The sensor streams glucose insights directly to the user’s phone and aims to offer a pain-free, longer-lasting alternative.
In a UK-based clinical trial involving 50 patients with type 1 and insulin-dependent type 2 diabetes, early data from 25 participants showed accurate glucose readings for up to 10 days—significantly outlasting many current sensors.
With promising results and fresh capital, Sava is poised to compete in the growing CGM market, emphasizing durability and comfort.
Follow MEDWIRE.AI for biosensor and diabetes tech breakthroughs.
